Neoadjuvant strategies for advanced pancreatic neuroendocrine tumors: should combined chemotherapy and peptide receptor radionuclide therapy be the preferred regimen for maximizing outcome?

With the evolution of peptide receptor radionuclide therapy (PRRT) in the mainstream management of metastatic/advanced neuroendocrine tumors (NETs), one area of particular interest is to define its place in the neoadjuvant setting of pancreatic NET and develop an effective and optimal clinical protocol for treatment, monitoring, and evaluation for surgical feasibility. Hence, it is worthwhile for the nuclear medicine fraternity to be aware of the nuances and the determinants so as to be able to deliver the most effective treatment to maximize the possibility of surgical resection.

[1]  S. Shrikhande,et al.  Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics , 2016, Nuclear medicine communications.

[2]  H. Kennecke,et al.  Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs. , 2014, Journal of gastrointestinal oncology.

[3]  M. Santoni,et al.  Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy , 2014, Gastroenterology research and practice.

[4]  M. Silverstein,et al.  DCIS Treated with Excision Alone Using the National Comprehensive Cancer Network (NCCN) Guidelines , 2013, Annals of Surgical Oncology.

[5]  J. Chabot,et al.  Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience , 2013, Cancer Chemotherapy and Pharmacology.

[6]  J. Turner,et al.  Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. , 2012, Cancer biotherapy & radiopharmaceuticals.

[7]  D. Coppola,et al.  First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas , 2011, Cancer.

[8]  O. Stoeltzing,et al.  Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor , 2010, Langenbeck's Archives of Surgery.

[9]  G. Klöppel,et al.  Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. , 2009, World journal of gastroenterology.

[10]  Kenneth J. Chang,et al.  Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement , 2009, Annals of Surgical Oncology.

[11]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Fine,et al.  Effective treatment of neuroendocrine tumors With temozolomide and capecitabine , 2005 .

[13]  L. Kvols,et al.  Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms , 1991, Cancer.

[14]  H. Biersack,et al.  Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors. , 2012, Clinical nuclear medicine.